ALDX
Income statement / Annual
Last year (2024), Aldeyra Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Aldeyra Therapeutics, Inc.'s net income was -$55.85 M.
See Aldeyra Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$56.22 K
|
$96.31 K
|
$71.00 K
|
$37.85 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$56.22 K
|
-$96.31 K
|
-$71.00 K
|
-$37.85 K
|
-$35.79 K
|
-$18.78 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$48.22 M
|
$29.46 M
|
$47.31 M
|
$44.94 M
|
$24.68 M
|
$44.35 M
|
$29.82 M
|
$16.30 M
|
$13.18 M
|
$7.57 M
|
| General & Administrative Expenses |
$11.89 M
|
$13.34 M
|
$15.37 M
|
$11.28 M
|
$0.00
|
$12.16 M
|
$9.88 M
|
$6.19 M
|
$5.52 M
|
$4.42 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.89 M
|
$13.34 M
|
$15.37 M
|
$11.28 M
|
$9.93 M
|
$12.16 M
|
$9.88 M
|
$6.19 M
|
$5.52 M
|
$4.42 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$60.12 M
|
$42.79 M
|
$62.68 M
|
$56.22 M
|
$34.61 M
|
$56.51 M
|
$39.70 M
|
$22.49 M
|
$18.70 M
|
$11.99 M
|
| Cost And Expenses |
$60.12 M
|
$42.79 M
|
$62.68 M
|
$56.22 M
|
$34.67 M
|
$63.07 M
|
$39.70 M
|
$22.49 M
|
$18.70 M
|
$11.99 M
|
| Interest Income |
$6.19 M
|
$7.32 M
|
$2.35 M
|
$185.36 K
|
$292.22 K
|
$1.54 M
|
$952.70 K
|
$261.25 K
|
$102.04 K
|
$11.13 K
|
| Interest Expense |
$1.93 M
|
$2.07 M
|
$1.69 M
|
$1.74 M
|
$1.90 M
|
$603.85 K
|
$146.79 K
|
$113.45 K
|
$105.51 K
|
$112.31 K
|
| Depreciation & Amortization |
$249.62 K
|
$262.78 K
|
$258.71 K
|
$264.18 K
|
$56.22 K
|
$96.31 K
|
$71.00 K
|
$37.85 K
|
$35.79 K
|
$18.78 K
|
| EBITDA |
-$53.68 M |
-$35.21 M |
-$60.07 M |
-$55.77 M |
-$36.07 M |
-$61.44 M |
-$38.68 M |
-$22.19 M |
-$18.56 M |
-$11.96 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.27 M
|
$5.25 M
|
$655.35 K
|
-$1.56 M
|
-$3.37 M
|
$0.00
|
$805.91 K
|
$147.80 K
|
-$3.47 K
|
-$101.00 K
|
| Income Before Tax |
-$55.85 M
|
-$37.54 M
|
-$62.02 M
|
-$57.78 M
|
-$38.03 M
|
-$62.14 M
|
-$38.89 M
|
-$22.34 M
|
-$18.70 M
|
-$12.09 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$479.27 K
|
-$1.31 M
|
$0.00
|
$223.40 K
|
$66.25 K
|
-$7.65 K
|
| Net Income |
-$55.85 M
|
-$37.54 M
|
-$62.02 M
|
-$57.78 M
|
-$37.55 M
|
-$60.83 M
|
-$38.89 M
|
-$22.34 M
|
-$18.70 M
|
-$12.09 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.94 |
-0.64 |
-1.06 |
-1.07 |
-1.11 |
-2.24 |
-1.79 |
-1.4 |
-1.65 |
-1.4 |
| EPS Diluted |
-0.94 |
-0.64 |
-1.06 |
-1.07 |
-1.11 |
-2.24 |
-1.79 |
-1.4 |
-1.65 |
-1.4 |
| Weighted Average Shares Out |
$59.48 M
|
$58.94 M
|
$58.41 M
|
$54.04 M
|
$33.97 M
|
$27.11 M
|
$21.69 M
|
$15.92 M
|
$11.35 M
|
$8.63 M
|
| Weighted Average Shares Out Diluted |
$59.48 M
|
$58.94 M
|
$58.41 M
|
$54.04 M
|
$33.97 M
|
$27.11 M
|
$21.69 M
|
$15.92 M
|
$11.35 M
|
$8.63 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
